The levels of inflammatory cytokines of interleukin (IL)‐6, interferon (IFN)‐γ, and tumor necrosis factor (TNF)‐α in serum can be regulated by the treatment with MX (Figure 1E), so did the tumor biomarker levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, and CA242 in the group treated with MX (Figure 1F). The gene discussed is CEACAM5; the disease is neoplasm.